Patient-specific hiPSC bioprocessing for drug screening: Bioprocess economics and optimisation
• A bioprocess economics model for patient-specific cell line production is described. • Cost of goods and robustness are determined for automated versus manual bioprocessing. • The impact of throughput and scale on the ranking of the bioprocess options is explored. • The number of PSC expansion sta...
Ausführliche Beschreibung
Autor*in: |
Jenkins, Michael [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2016 |
---|
Schlagwörter: |
---|
Umfang: |
14 |
---|
Übergeordnetes Werk: |
Enthalten in: Biofuel recovery from microalgae biomass grown in dairy wastewater treated with activated sludge: The next step in sustainable production - de Mendonça, Henrique Vieira ELSEVIER, 2022, an international journal of research and development, Amsterdam [u.a.] |
---|---|
Übergeordnetes Werk: |
volume:108 ; year:2016 ; day:15 ; month:04 ; pages:84-97 ; extent:14 |
Links: |
---|
DOI / URN: |
10.1016/j.bej.2015.09.024 |
---|
Katalog-ID: |
ELV029478022 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | ELV029478022 | ||
003 | DE-627 | ||
005 | 20230623201351.0 | ||
007 | cr uuu---uuuuu | ||
008 | 180603s2016 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.bej.2015.09.024 |2 doi | |
028 | 5 | 2 | |a GBVA2016002000025.pica |
035 | |a (DE-627)ELV029478022 | ||
035 | |a (ELSEVIER)S1369-703X(15)30069-3 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | |a 660 |a 540 | |
082 | 0 | 4 | |a 660 |q DE-600 |
082 | 0 | 4 | |a 540 |q DE-600 |
082 | 0 | 4 | |a 333.7 |a 610 |q VZ |
084 | |a 43.12 |2 bkl | ||
084 | |a 43.13 |2 bkl | ||
084 | |a 44.13 |2 bkl | ||
100 | 1 | |a Jenkins, Michael |e verfasserin |4 aut | |
245 | 1 | 0 | |a Patient-specific hiPSC bioprocessing for drug screening: Bioprocess economics and optimisation |
264 | 1 | |c 2016 | |
300 | |a 14 | ||
336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
337 | |a nicht spezifiziert |b z |2 rdamedia | ||
338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
520 | |a • A bioprocess economics model for patient-specific cell line production is described. • Cost of goods and robustness are determined for automated versus manual bioprocessing. • The impact of throughput and scale on the ranking of the bioprocess options is explored. • The number of PSC expansion stages is the key process economics driver in both processes. • Process optimization required to achieve acceptable cost of goods figures is predicted. | ||
650 | 7 | |a NCE |2 Elsevier | |
650 | 7 | |a PSC |2 Elsevier | |
650 | 7 | |a CTS |2 Elsevier | |
650 | 7 | |a HTS |2 Elsevier | |
650 | 7 | |a iPSC |2 Elsevier | |
650 | 7 | |a hPSC |2 Elsevier | |
650 | 7 | |a COG |2 Elsevier | |
650 | 7 | |a FCI |2 Elsevier | |
650 | 7 | |a PCA |2 Elsevier | |
650 | 7 | |a PBP |2 Elsevier | |
700 | 1 | |a Bilsland, James |4 oth | |
700 | 1 | |a Allsopp, Timothy E. |4 oth | |
700 | 1 | |a Ho, Sa V. |4 oth | |
700 | 1 | |a Farid, Suzanne S. |4 oth | |
773 | 0 | 8 | |i Enthalten in |n Elsevier |a de Mendonça, Henrique Vieira ELSEVIER |t Biofuel recovery from microalgae biomass grown in dairy wastewater treated with activated sludge: The next step in sustainable production |d 2022 |d an international journal of research and development |g Amsterdam [u.a.] |w (DE-627)ELV007707568 |
773 | 1 | 8 | |g volume:108 |g year:2016 |g day:15 |g month:04 |g pages:84-97 |g extent:14 |
856 | 4 | 0 | |u https://doi.org/10.1016/j.bej.2015.09.024 |3 Volltext |
912 | |a GBV_USEFLAG_U | ||
912 | |a GBV_ELV | ||
912 | |a SYSFLAG_U | ||
912 | |a SSG-OLC-PHA | ||
912 | |a SSG-OPC-GGO | ||
936 | b | k | |a 43.12 |j Umweltchemie |q VZ |
936 | b | k | |a 43.13 |j Umwelttoxikologie |q VZ |
936 | b | k | |a 44.13 |j Medizinische Ökologie |q VZ |
951 | |a AR | ||
952 | |d 108 |j 2016 |b 15 |c 0415 |h 84-97 |g 14 | ||
953 | |2 045F |a 660 |
author_variant |
m j mj |
---|---|
matchkey_str |
jenkinsmichaelbilslandjamesallsopptimoth:2016----:ainseiihpcipoesnfrrgcennborcse |
hierarchy_sort_str |
2016 |
bklnumber |
43.12 43.13 44.13 |
publishDate |
2016 |
allfields |
10.1016/j.bej.2015.09.024 doi GBVA2016002000025.pica (DE-627)ELV029478022 (ELSEVIER)S1369-703X(15)30069-3 DE-627 ger DE-627 rakwb eng 660 540 660 DE-600 540 DE-600 333.7 610 VZ 43.12 bkl 43.13 bkl 44.13 bkl Jenkins, Michael verfasserin aut Patient-specific hiPSC bioprocessing for drug screening: Bioprocess economics and optimisation 2016 14 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • A bioprocess economics model for patient-specific cell line production is described. • Cost of goods and robustness are determined for automated versus manual bioprocessing. • The impact of throughput and scale on the ranking of the bioprocess options is explored. • The number of PSC expansion stages is the key process economics driver in both processes. • Process optimization required to achieve acceptable cost of goods figures is predicted. NCE Elsevier PSC Elsevier CTS Elsevier HTS Elsevier iPSC Elsevier hPSC Elsevier COG Elsevier FCI Elsevier PCA Elsevier PBP Elsevier Bilsland, James oth Allsopp, Timothy E. oth Ho, Sa V. oth Farid, Suzanne S. oth Enthalten in Elsevier de Mendonça, Henrique Vieira ELSEVIER Biofuel recovery from microalgae biomass grown in dairy wastewater treated with activated sludge: The next step in sustainable production 2022 an international journal of research and development Amsterdam [u.a.] (DE-627)ELV007707568 volume:108 year:2016 day:15 month:04 pages:84-97 extent:14 https://doi.org/10.1016/j.bej.2015.09.024 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA SSG-OPC-GGO 43.12 Umweltchemie VZ 43.13 Umwelttoxikologie VZ 44.13 Medizinische Ökologie VZ AR 108 2016 15 0415 84-97 14 045F 660 |
spelling |
10.1016/j.bej.2015.09.024 doi GBVA2016002000025.pica (DE-627)ELV029478022 (ELSEVIER)S1369-703X(15)30069-3 DE-627 ger DE-627 rakwb eng 660 540 660 DE-600 540 DE-600 333.7 610 VZ 43.12 bkl 43.13 bkl 44.13 bkl Jenkins, Michael verfasserin aut Patient-specific hiPSC bioprocessing for drug screening: Bioprocess economics and optimisation 2016 14 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • A bioprocess economics model for patient-specific cell line production is described. • Cost of goods and robustness are determined for automated versus manual bioprocessing. • The impact of throughput and scale on the ranking of the bioprocess options is explored. • The number of PSC expansion stages is the key process economics driver in both processes. • Process optimization required to achieve acceptable cost of goods figures is predicted. NCE Elsevier PSC Elsevier CTS Elsevier HTS Elsevier iPSC Elsevier hPSC Elsevier COG Elsevier FCI Elsevier PCA Elsevier PBP Elsevier Bilsland, James oth Allsopp, Timothy E. oth Ho, Sa V. oth Farid, Suzanne S. oth Enthalten in Elsevier de Mendonça, Henrique Vieira ELSEVIER Biofuel recovery from microalgae biomass grown in dairy wastewater treated with activated sludge: The next step in sustainable production 2022 an international journal of research and development Amsterdam [u.a.] (DE-627)ELV007707568 volume:108 year:2016 day:15 month:04 pages:84-97 extent:14 https://doi.org/10.1016/j.bej.2015.09.024 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA SSG-OPC-GGO 43.12 Umweltchemie VZ 43.13 Umwelttoxikologie VZ 44.13 Medizinische Ökologie VZ AR 108 2016 15 0415 84-97 14 045F 660 |
allfields_unstemmed |
10.1016/j.bej.2015.09.024 doi GBVA2016002000025.pica (DE-627)ELV029478022 (ELSEVIER)S1369-703X(15)30069-3 DE-627 ger DE-627 rakwb eng 660 540 660 DE-600 540 DE-600 333.7 610 VZ 43.12 bkl 43.13 bkl 44.13 bkl Jenkins, Michael verfasserin aut Patient-specific hiPSC bioprocessing for drug screening: Bioprocess economics and optimisation 2016 14 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • A bioprocess economics model for patient-specific cell line production is described. • Cost of goods and robustness are determined for automated versus manual bioprocessing. • The impact of throughput and scale on the ranking of the bioprocess options is explored. • The number of PSC expansion stages is the key process economics driver in both processes. • Process optimization required to achieve acceptable cost of goods figures is predicted. NCE Elsevier PSC Elsevier CTS Elsevier HTS Elsevier iPSC Elsevier hPSC Elsevier COG Elsevier FCI Elsevier PCA Elsevier PBP Elsevier Bilsland, James oth Allsopp, Timothy E. oth Ho, Sa V. oth Farid, Suzanne S. oth Enthalten in Elsevier de Mendonça, Henrique Vieira ELSEVIER Biofuel recovery from microalgae biomass grown in dairy wastewater treated with activated sludge: The next step in sustainable production 2022 an international journal of research and development Amsterdam [u.a.] (DE-627)ELV007707568 volume:108 year:2016 day:15 month:04 pages:84-97 extent:14 https://doi.org/10.1016/j.bej.2015.09.024 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA SSG-OPC-GGO 43.12 Umweltchemie VZ 43.13 Umwelttoxikologie VZ 44.13 Medizinische Ökologie VZ AR 108 2016 15 0415 84-97 14 045F 660 |
allfieldsGer |
10.1016/j.bej.2015.09.024 doi GBVA2016002000025.pica (DE-627)ELV029478022 (ELSEVIER)S1369-703X(15)30069-3 DE-627 ger DE-627 rakwb eng 660 540 660 DE-600 540 DE-600 333.7 610 VZ 43.12 bkl 43.13 bkl 44.13 bkl Jenkins, Michael verfasserin aut Patient-specific hiPSC bioprocessing for drug screening: Bioprocess economics and optimisation 2016 14 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • A bioprocess economics model for patient-specific cell line production is described. • Cost of goods and robustness are determined for automated versus manual bioprocessing. • The impact of throughput and scale on the ranking of the bioprocess options is explored. • The number of PSC expansion stages is the key process economics driver in both processes. • Process optimization required to achieve acceptable cost of goods figures is predicted. NCE Elsevier PSC Elsevier CTS Elsevier HTS Elsevier iPSC Elsevier hPSC Elsevier COG Elsevier FCI Elsevier PCA Elsevier PBP Elsevier Bilsland, James oth Allsopp, Timothy E. oth Ho, Sa V. oth Farid, Suzanne S. oth Enthalten in Elsevier de Mendonça, Henrique Vieira ELSEVIER Biofuel recovery from microalgae biomass grown in dairy wastewater treated with activated sludge: The next step in sustainable production 2022 an international journal of research and development Amsterdam [u.a.] (DE-627)ELV007707568 volume:108 year:2016 day:15 month:04 pages:84-97 extent:14 https://doi.org/10.1016/j.bej.2015.09.024 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA SSG-OPC-GGO 43.12 Umweltchemie VZ 43.13 Umwelttoxikologie VZ 44.13 Medizinische Ökologie VZ AR 108 2016 15 0415 84-97 14 045F 660 |
allfieldsSound |
10.1016/j.bej.2015.09.024 doi GBVA2016002000025.pica (DE-627)ELV029478022 (ELSEVIER)S1369-703X(15)30069-3 DE-627 ger DE-627 rakwb eng 660 540 660 DE-600 540 DE-600 333.7 610 VZ 43.12 bkl 43.13 bkl 44.13 bkl Jenkins, Michael verfasserin aut Patient-specific hiPSC bioprocessing for drug screening: Bioprocess economics and optimisation 2016 14 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • A bioprocess economics model for patient-specific cell line production is described. • Cost of goods and robustness are determined for automated versus manual bioprocessing. • The impact of throughput and scale on the ranking of the bioprocess options is explored. • The number of PSC expansion stages is the key process economics driver in both processes. • Process optimization required to achieve acceptable cost of goods figures is predicted. NCE Elsevier PSC Elsevier CTS Elsevier HTS Elsevier iPSC Elsevier hPSC Elsevier COG Elsevier FCI Elsevier PCA Elsevier PBP Elsevier Bilsland, James oth Allsopp, Timothy E. oth Ho, Sa V. oth Farid, Suzanne S. oth Enthalten in Elsevier de Mendonça, Henrique Vieira ELSEVIER Biofuel recovery from microalgae biomass grown in dairy wastewater treated with activated sludge: The next step in sustainable production 2022 an international journal of research and development Amsterdam [u.a.] (DE-627)ELV007707568 volume:108 year:2016 day:15 month:04 pages:84-97 extent:14 https://doi.org/10.1016/j.bej.2015.09.024 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA SSG-OPC-GGO 43.12 Umweltchemie VZ 43.13 Umwelttoxikologie VZ 44.13 Medizinische Ökologie VZ AR 108 2016 15 0415 84-97 14 045F 660 |
language |
English |
source |
Enthalten in Biofuel recovery from microalgae biomass grown in dairy wastewater treated with activated sludge: The next step in sustainable production Amsterdam [u.a.] volume:108 year:2016 day:15 month:04 pages:84-97 extent:14 |
sourceStr |
Enthalten in Biofuel recovery from microalgae biomass grown in dairy wastewater treated with activated sludge: The next step in sustainable production Amsterdam [u.a.] volume:108 year:2016 day:15 month:04 pages:84-97 extent:14 |
format_phy_str_mv |
Article |
bklname |
Umweltchemie Umwelttoxikologie Medizinische Ökologie |
institution |
findex.gbv.de |
topic_facet |
NCE PSC CTS HTS iPSC hPSC COG FCI PCA PBP |
dewey-raw |
660 |
isfreeaccess_bool |
false |
container_title |
Biofuel recovery from microalgae biomass grown in dairy wastewater treated with activated sludge: The next step in sustainable production |
authorswithroles_txt_mv |
Jenkins, Michael @@aut@@ Bilsland, James @@oth@@ Allsopp, Timothy E. @@oth@@ Ho, Sa V. @@oth@@ Farid, Suzanne S. @@oth@@ |
publishDateDaySort_date |
2016-01-15T00:00:00Z |
hierarchy_top_id |
ELV007707568 |
dewey-sort |
3660 |
id |
ELV029478022 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV029478022</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623201351.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2016 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.bej.2015.09.024</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2016002000025.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV029478022</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1369-703X(15)30069-3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">660</subfield><subfield code="a">540</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">660</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">333.7</subfield><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">43.12</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">43.13</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.13</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Jenkins, Michael</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Patient-specific hiPSC bioprocessing for drug screening: Bioprocess economics and optimisation</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">14</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• A bioprocess economics model for patient-specific cell line production is described. • Cost of goods and robustness are determined for automated versus manual bioprocessing. • The impact of throughput and scale on the ranking of the bioprocess options is explored. • The number of PSC expansion stages is the key process economics driver in both processes. • Process optimization required to achieve acceptable cost of goods figures is predicted.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">NCE</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PSC</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CTS</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HTS</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">iPSC</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">hPSC</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">COG</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">FCI</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PCA</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PBP</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bilsland, James</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Allsopp, Timothy E.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ho, Sa V.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Farid, Suzanne S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">de Mendonça, Henrique Vieira ELSEVIER</subfield><subfield code="t">Biofuel recovery from microalgae biomass grown in dairy wastewater treated with activated sludge: The next step in sustainable production</subfield><subfield code="d">2022</subfield><subfield code="d">an international journal of research and development</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV007707568</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:108</subfield><subfield code="g">year:2016</subfield><subfield code="g">day:15</subfield><subfield code="g">month:04</subfield><subfield code="g">pages:84-97</subfield><subfield code="g">extent:14</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.bej.2015.09.024</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-GGO</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">43.12</subfield><subfield code="j">Umweltchemie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">43.13</subfield><subfield code="j">Umwelttoxikologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.13</subfield><subfield code="j">Medizinische Ökologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">108</subfield><subfield code="j">2016</subfield><subfield code="b">15</subfield><subfield code="c">0415</subfield><subfield code="h">84-97</subfield><subfield code="g">14</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">660</subfield></datafield></record></collection>
|
author |
Jenkins, Michael |
spellingShingle |
Jenkins, Michael ddc 660 ddc 540 ddc 333.7 bkl 43.12 bkl 43.13 bkl 44.13 Elsevier NCE Elsevier PSC Elsevier CTS Elsevier HTS Elsevier iPSC Elsevier hPSC Elsevier COG Elsevier FCI Elsevier PCA Elsevier PBP Patient-specific hiPSC bioprocessing for drug screening: Bioprocess economics and optimisation |
authorStr |
Jenkins, Michael |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV007707568 |
format |
electronic Article |
dewey-ones |
660 - Chemical engineering 540 - Chemistry & allied sciences 333 - Economics of land & energy 610 - Medicine & health |
delete_txt_mv |
keep |
author_role |
aut |
collection |
elsevier |
remote_str |
true |
illustrated |
Not Illustrated |
topic_title |
660 540 660 DE-600 540 DE-600 333.7 610 VZ 43.12 bkl 43.13 bkl 44.13 bkl Patient-specific hiPSC bioprocessing for drug screening: Bioprocess economics and optimisation NCE Elsevier PSC Elsevier CTS Elsevier HTS Elsevier iPSC Elsevier hPSC Elsevier COG Elsevier FCI Elsevier PCA Elsevier PBP Elsevier |
topic |
ddc 660 ddc 540 ddc 333.7 bkl 43.12 bkl 43.13 bkl 44.13 Elsevier NCE Elsevier PSC Elsevier CTS Elsevier HTS Elsevier iPSC Elsevier hPSC Elsevier COG Elsevier FCI Elsevier PCA Elsevier PBP |
topic_unstemmed |
ddc 660 ddc 540 ddc 333.7 bkl 43.12 bkl 43.13 bkl 44.13 Elsevier NCE Elsevier PSC Elsevier CTS Elsevier HTS Elsevier iPSC Elsevier hPSC Elsevier COG Elsevier FCI Elsevier PCA Elsevier PBP |
topic_browse |
ddc 660 ddc 540 ddc 333.7 bkl 43.12 bkl 43.13 bkl 44.13 Elsevier NCE Elsevier PSC Elsevier CTS Elsevier HTS Elsevier iPSC Elsevier hPSC Elsevier COG Elsevier FCI Elsevier PCA Elsevier PBP |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
zu |
author2_variant |
j b jb t e a te tea s v h sv svh s s f ss ssf |
hierarchy_parent_title |
Biofuel recovery from microalgae biomass grown in dairy wastewater treated with activated sludge: The next step in sustainable production |
hierarchy_parent_id |
ELV007707568 |
dewey-tens |
660 - Chemical engineering 540 - Chemistry 330 - Economics 610 - Medicine & health |
hierarchy_top_title |
Biofuel recovery from microalgae biomass grown in dairy wastewater treated with activated sludge: The next step in sustainable production |
isfreeaccess_txt |
false |
familylinks_str_mv |
(DE-627)ELV007707568 |
title |
Patient-specific hiPSC bioprocessing for drug screening: Bioprocess economics and optimisation |
ctrlnum |
(DE-627)ELV029478022 (ELSEVIER)S1369-703X(15)30069-3 |
title_full |
Patient-specific hiPSC bioprocessing for drug screening: Bioprocess economics and optimisation |
author_sort |
Jenkins, Michael |
journal |
Biofuel recovery from microalgae biomass grown in dairy wastewater treated with activated sludge: The next step in sustainable production |
journalStr |
Biofuel recovery from microalgae biomass grown in dairy wastewater treated with activated sludge: The next step in sustainable production |
lang_code |
eng |
isOA_bool |
false |
dewey-hundreds |
600 - Technology 500 - Science 300 - Social sciences |
recordtype |
marc |
publishDateSort |
2016 |
contenttype_str_mv |
zzz |
container_start_page |
84 |
author_browse |
Jenkins, Michael |
container_volume |
108 |
physical |
14 |
class |
660 540 660 DE-600 540 DE-600 333.7 610 VZ 43.12 bkl 43.13 bkl 44.13 bkl |
format_se |
Elektronische Aufsätze |
author-letter |
Jenkins, Michael |
doi_str_mv |
10.1016/j.bej.2015.09.024 |
dewey-full |
660 540 333.7 610 |
title_sort |
patient-specific hipsc bioprocessing for drug screening: bioprocess economics and optimisation |
title_auth |
Patient-specific hiPSC bioprocessing for drug screening: Bioprocess economics and optimisation |
abstract |
• A bioprocess economics model for patient-specific cell line production is described. • Cost of goods and robustness are determined for automated versus manual bioprocessing. • The impact of throughput and scale on the ranking of the bioprocess options is explored. • The number of PSC expansion stages is the key process economics driver in both processes. • Process optimization required to achieve acceptable cost of goods figures is predicted. |
abstractGer |
• A bioprocess economics model for patient-specific cell line production is described. • Cost of goods and robustness are determined for automated versus manual bioprocessing. • The impact of throughput and scale on the ranking of the bioprocess options is explored. • The number of PSC expansion stages is the key process economics driver in both processes. • Process optimization required to achieve acceptable cost of goods figures is predicted. |
abstract_unstemmed |
• A bioprocess economics model for patient-specific cell line production is described. • Cost of goods and robustness are determined for automated versus manual bioprocessing. • The impact of throughput and scale on the ranking of the bioprocess options is explored. • The number of PSC expansion stages is the key process economics driver in both processes. • Process optimization required to achieve acceptable cost of goods figures is predicted. |
collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA SSG-OPC-GGO |
title_short |
Patient-specific hiPSC bioprocessing for drug screening: Bioprocess economics and optimisation |
url |
https://doi.org/10.1016/j.bej.2015.09.024 |
remote_bool |
true |
author2 |
Bilsland, James Allsopp, Timothy E. Ho, Sa V. Farid, Suzanne S. |
author2Str |
Bilsland, James Allsopp, Timothy E. Ho, Sa V. Farid, Suzanne S. |
ppnlink |
ELV007707568 |
mediatype_str_mv |
z |
isOA_txt |
false |
hochschulschrift_bool |
false |
author2_role |
oth oth oth oth |
doi_str |
10.1016/j.bej.2015.09.024 |
up_date |
2024-07-06T21:34:20.369Z |
_version_ |
1803867033824133120 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV029478022</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623201351.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2016 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.bej.2015.09.024</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2016002000025.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV029478022</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1369-703X(15)30069-3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">660</subfield><subfield code="a">540</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">660</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">333.7</subfield><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">43.12</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">43.13</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.13</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Jenkins, Michael</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Patient-specific hiPSC bioprocessing for drug screening: Bioprocess economics and optimisation</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">14</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• A bioprocess economics model for patient-specific cell line production is described. • Cost of goods and robustness are determined for automated versus manual bioprocessing. • The impact of throughput and scale on the ranking of the bioprocess options is explored. • The number of PSC expansion stages is the key process economics driver in both processes. • Process optimization required to achieve acceptable cost of goods figures is predicted.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">NCE</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PSC</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CTS</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HTS</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">iPSC</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">hPSC</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">COG</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">FCI</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PCA</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PBP</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bilsland, James</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Allsopp, Timothy E.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ho, Sa V.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Farid, Suzanne S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">de Mendonça, Henrique Vieira ELSEVIER</subfield><subfield code="t">Biofuel recovery from microalgae biomass grown in dairy wastewater treated with activated sludge: The next step in sustainable production</subfield><subfield code="d">2022</subfield><subfield code="d">an international journal of research and development</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV007707568</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:108</subfield><subfield code="g">year:2016</subfield><subfield code="g">day:15</subfield><subfield code="g">month:04</subfield><subfield code="g">pages:84-97</subfield><subfield code="g">extent:14</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.bej.2015.09.024</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-GGO</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">43.12</subfield><subfield code="j">Umweltchemie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">43.13</subfield><subfield code="j">Umwelttoxikologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.13</subfield><subfield code="j">Medizinische Ökologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">108</subfield><subfield code="j">2016</subfield><subfield code="b">15</subfield><subfield code="c">0415</subfield><subfield code="h">84-97</subfield><subfield code="g">14</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">660</subfield></datafield></record></collection>
|
score |
7.4004498 |